RNA Editing

Showing 1607 articles

Sanofi Halts mRNA Flu Vaccine Trial Amid Surging U.S. Influenza Season

French pharmaceutical giant Sanofi has discontinued development of its experimental mRNA flu vaccine, citing a strategic reprioritization. The decision comes as influenza activity remains high across much of the United States, with significant hospitalizations and deaths reported this season.

Business

OneSpan's Surging Returns on Capital Signal a Turnaround Story

Amid a challenging period for its share price, cybersecurity firm OneSpan is demonstrating a powerful operational turnaround, with its return on capital employed (ROCE) skyrocketing. This key profitability metric now vastly outpaces the industry, suggesting past investments are paying off and warranting a closer look from investors.

Business

MSM International's Capital Efficiency Gains Signal Potential for Sustained Growth

MSM International (Catalist: 51O) is demonstrating a promising trajectory in capital efficiency, with its Return on Capital Employed (ROCE) showing improvement. While the current 5.5% ROCE is modest, its alignment with industry averages and the context of a recent turnaround from losses paints a picture of a company methodically enhancing its profitability. Investors are taking note, as reflected in a significant 110% total return over the past five years.

Business

Nike Investigates Major Data Breach Claim Amid Turnaround Efforts

Sportswear giant Nike is probing claims by a ransomware group that it has leaked a trove of internal company data. The alleged breach, which comes as Nike navigates restructuring and margin pressures, raises significant questions about cybersecurity readiness and potential impacts on its digital transformation strategy.

Business

Gap's Stock Surge: Is the Turnaround Story Already Priced In?

Gap's shares have soared over 100% in three years, fueled by a remarkable operational turnaround. But as the stock hovers near $28, investors are asking: does the current price fairly reflect the future, or has the market run ahead of itself? A deep dive into valuation metrics reveals a mixed picture.